Table 1.

Characteristics of selected eosinophil selective biologics.

	Mepolizumab	Reslizumab	Benralizumab	Lirentelimab
Target	IL-5	IL-5	IL-5Rα	Siglec-8
FDA approved Indications	-Asthma (age 6+) -EGPA (age 18+) -Idiopathic HES (age 12+) -CRSwNP (age 18+)	-Asthma (age 18+)	-Asthma (age 12+)	-None
Dose	-Asthma age 12+ and CRSwNP: 100 mg SC every 4 weeks -Asthma age 6–11:40 mg SC every 4 weeks -EGPA and HES: 300 mg SC every 4 weeks	-3 mg/kg IV every 4 weeks	-30 mg SC every 4 weeks for 3 doses, then every 8 weeks	-N/A
Ongoing Clinical Trials	-EGPA -EoE -CSU -Eosinophilic fasciitis -Gleich syndrome -COPD exacerbation with eosinophilia	-CRS	-EGPA -HES -CRSwNP -EoE -EGID -CSU -AD -ABPA -Bullous pemphigoid	-EoE -EGID -CSU

Abbreviations: IL-5, Interleukin 5; IL-5Rα, IL-5 receptor alpha subunit; Siglec-8, sialic acid-binding immunoglobulin-like lectin 8; EGPA, eosinophilic granulomatosis with polyangiitis; HES, hypereosinophilic syndrome; SC, subcutaneous; IV, intravenous; CRSwNP, chronic rhinosinusitis with nasal polyposis; EoE, eosinophilic esophagitis; CSU, chronic spontaneous urticaria; COPD, chronic obstructive pulmonary disease; EGID, eosinophilic gastrointestinal disease; AD, atopic dermatitis; ABPA, allergic bronchopulmonary aspergillosis